Half-year report · Q2

Period2024-01-01 → 2024-06-30
Filed2024-08-02
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 56
MetricValuePeriodScopeSource row
Revenue¥1.11T2024-01-01 → 2024-06-30Cons.Revenue IFRS
Revenue¥589.4bn2024-04-01 → 2024-06-30dCons.Revenue IFRS
Revenue¥2.02T2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥947.5bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥499.2bn2023-04-01 → 2023-06-30dCons.Revenue IFRS
Operating income¥126.3bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Operating income¥34.3bn2024-04-01 → 2024-06-30dCons.Operating profit loss IFRS
Operating income¥130.7bn2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥53.9bn2023-04-01 → 2023-06-30dCons.Operating profit loss IFRS
Profit before tax¥142.2bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Profit before tax¥42.1bn2024-04-01 → 2024-06-30dCons.Profit loss before tax IFRS
Profit before tax¥142.7bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥138.8bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥59.6bn2023-04-01 → 2023-06-30dCons.Profit loss before tax IFRS
Net income (owners)¥107.8bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥30.4bn2024-04-01 → 2024-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥121.6bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥102.6bn2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥41.2bn2023-04-01 → 2023-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥110.6bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Net income¥31.7bn2024-04-01 → 2024-06-30dCons.Profit loss IFRS
Net income¥105.1bn2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥42.4bn2023-04-01 → 2023-06-30dCons.Profit loss IFRS
Total assets¥3.66Tat 2024-06-30Cons.Assets IFRS
Total assets¥3.36Tat 2023-12-31Cons.Assets IFRS
Total assets¥3.31Tat 2023-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥993.9bnat 2024-06-30Cons.Liabilities IFRS
Total liabilities¥924.9bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥2.67Tat 2024-06-30Cons.Equity IFRS
Net assets / equity¥2.44Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥2.47Tat 2023-06-30Cons.Equity IFRS
Net assets / equity¥2.26Tat 2022-12-31dCons.Equity IFRS
Equity (owners)¥2.62Tat 2024-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.39Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.43Tat 2023-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥485.9bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥513.3bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥498.7bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥471.6bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥133.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥283.2bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥113.5bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥159.2bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥190.5bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥54.3bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥26.2bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥60.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥46.8bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥198.612024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥56.032024-04-01 → 2024-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥224.12023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥189.062023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥75.852023-04-01 → 2023-06-30dCons.Basic earnings loss per share IFRS
Equity ratio71.6%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.2%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio73.4%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 88
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-01-01 → 2024-06-30¥56.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-04-01 → 2024-06-30¥29.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-01-01 → 2024-06-30¥54.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-04-01 → 2024-06-30¥28.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-01-01 → 2024-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-04-01 → 2024-06-30¥880m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-01-01 → 2024-06-30¥4.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-04-01 → 2024-06-30¥2.9bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥1.8bn
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-06-30−¥890m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥1.8bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-06-30−¥890m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥24.2bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-06-30−¥13.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2024-01-01 → 2024-06-30¥15.7bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2024-04-01 → 2024-06-30¥8.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2024-01-01 → 2024-06-30¥15.7bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2024-04-01 → 2024-06-30¥8.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥3m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2024-04-01 → 2024-06-30¥1m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2024-01-01 → 2024-06-30¥12.3bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2024-04-01 → 2024-06-30¥8.0bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2024-01-01 → 2024-06-30¥271.8bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2024-04-01 → 2024-06-30¥145.6bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2024-01-01 → 2024-06-30¥271.8bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2024-04-01 → 2024-06-30¥145.6bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥15m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2024-04-01 → 2024-06-30¥8m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2024-01-01 → 2024-06-30¥37.3bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2024-04-01 → 2024-06-30¥20.5bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-06-30¥766.7bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2024-04-01 → 2024-06-30¥407.1bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-06-30¥766.7bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2024-04-01 → 2024-06-30¥407.1bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-06-30¥96.0bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2024-04-01 → 2024-06-30¥16.2bn
—segment totalrevenue2024-01-01 → 2024-06-30¥1.11T
—segment totalrevenue2024-04-01 → 2024-06-30¥590.3bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥1.11T
—segment totalrevenue external2024-04-01 → 2024-06-30¥589.4bn
—segment totalrevenue intersegment2024-01-01 → 2024-06-30¥1.8bn
—segment totalrevenue intersegment2024-04-01 → 2024-06-30¥890m
—segment totalsegment profit2024-01-01 → 2024-06-30¥150.5bn
—segment totalsegment profit2024-04-01 → 2024-06-30¥47.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-06-30¥55.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥27.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-06-30¥53.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥26.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-06-30¥1.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥920m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-06-30¥4.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30¥1.5bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥965m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥965m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥25.4bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥12.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2023-01-01 → 2023-06-30¥17.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2023-04-01 → 2023-06-30¥9.2bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2023-01-01 → 2023-06-30¥17.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2023-04-01 → 2023-06-30¥9.2bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥9m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥4m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2023-01-01 → 2023-06-30¥8.1bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2023-04-01 → 2023-06-30¥5.8bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2023-01-01 → 2023-06-30¥226.2bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2023-04-01 → 2023-06-30¥122.2bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2023-01-01 → 2023-06-30¥226.2bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2023-04-01 → 2023-06-30¥122.2bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥54m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥40m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2023-01-01 → 2023-06-30¥7.0bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2023-04-01 → 2023-06-30−¥3.8bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-06-30¥650.4bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2023-04-01 → 2023-06-30¥340.9bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-06-30¥650.4bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2023-04-01 → 2023-06-30¥340.9bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-06-30¥136.3bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2023-04-01 → 2023-06-30¥62.7bn
—segment totalrevenue2023-01-01 → 2023-06-30¥949.2bn
—segment totalrevenue2023-04-01 → 2023-06-30¥500.2bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥947.5bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥499.2bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥1.7bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥965m
—segment totalsegment profit2023-01-01 → 2023-06-30¥156.1bn
—segment totalsegment profit2023-04-01 → 2023-06-30¥66.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 877
ItemContextValueUnit
Interest and dividends received ope cf IFRSCurrentYTDDuration12465000000JPY
Interest paid ope cf IFRSPrior1YTDDuration-1575000000JPY
Interest paid ope cf IFRSCurrentYTDDuration-2238000000JPY
Income taxes refund paid ope cf IFRSPrior1YTDDuration-46981000000JPY
Income taxes refund paid ope cf IFRSCurrentYTDDuration-45634000000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration113533000000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration133040000000JPY
Proceeds from sale of property plant and equipment inv cf IFRSPrior1YTDDuration216000000JPY
Proceeds from sale of property plant and equipment inv cf IFRSCurrentYTDDuration305000000JPY
Purchase of property plant and equipment inv cf IFRSPrior1YTDDuration-43004000000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYTDDuration-47699000000JPY
Purchase of intangible assets inv cf IFRSPrior1YTDDuration-3100000000JPY
Purchase of intangible assets inv cf IFRSCurrentYTDDuration-19919000000JPY
Proceeds from sale of investments inv cf IFRSPrior1YTDDuration12143000000JPY
Proceeds from sale of investments inv cf IFRSCurrentYTDDuration5027000000JPY
Purchase of investments inv cf IFRSPrior1YTDDuration-21750000000JPY
Purchase of investments inv cf IFRSCurrentYTDDuration-72220000000JPY
Payments for acquisition of subsidiaries inv cf IFRSPrior1YTDDuration-JPY
Payments for acquisition of subsidiaries inv cf IFRSCurrentYTDDuration-2601000000JPY
Net decrease increase in time deposits inv cf IFRSPrior1YTDDuration2274000000JPY
Net decrease increase in time deposits inv cf IFRSCurrentYTDDuration-22942000000JPY
Other inv cf IFRSPrior1YTDDuration-1113000000JPY
Other inv cf IFRSCurrentYTDDuration847000000JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration-54334000000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration-159203000000JPY
Payments for purchase of treasury shares fin cf IFRSPrior1YTDDuration-1000000JPY
Payments for purchase of treasury shares fin cf IFRSCurrentYTDDuration-1000000JPY
Net increase decrease in short term borrowings fin cf IFRSPrior1YTDDuration42000000JPY
Net increase decrease in short term borrowings fin cf IFRSCurrentYTDDuration43151000000JPY
Proceeds from long term borrowings fin cf IFRSPrior1YTDDuration11000000JPY
Proceeds from long term borrowings fin cf IFRSCurrentYTDDuration150000000JPY
Repayments of long term borrowings fin cf IFRSPrior1YTDDuration-8285000000JPY
Repayments of long term borrowings fin cf IFRSCurrentYTDDuration-3962000000JPY
Redemption of bonds fin cf IFRSPrior1YTDDuration-JPY
Redemption of bonds fin cf IFRSCurrentYTDDuration-20000000000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-10111000000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-11019000000JPY
Dividends paid fin cf IFRSPrior1YTDDuration-28450000000JPY
Dividends paid fin cf IFRSCurrentYTDDuration-34066000000JPY
Capital contribution from non controlling interests fin cf IFRSPrior1YTDDuration2021000000JPY
Capital contribution from non controlling interests fin cf IFRSCurrentYTDDuration-JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSPrior1YTDDuration-1980000000JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSCurrentYTDDuration-413000000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-46752000000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-26161000000JPY
Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRSPrior1YTDDuration12446000000JPY
Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRSCurrentYTDDuration-52323000000JPY
Cash and cash equivalents IFRSPrior2YearInstant471634000000JPY
Cash and cash equivalents IFRSPrior1YearInstant513341000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration14578000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass